Compare XPOF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | PROK |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.4M | 331.2M |
| IPO Year | 2021 | 2021 |
| Metric | XPOF | PROK |
|---|---|---|
| Price | $5.74 | $2.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $10.06 | $7.40 |
| AVG Volume (30 Days) | ★ 852.8K | 493.9K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,092,000.00 | $76,000.00 |
| Revenue This Year | N/A | $1,010.19 |
| Revenue Next Year | $5.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $0.46 |
| 52 Week High | $11.14 | $7.13 |
| Indicator | XPOF | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 48.91 |
| Support Level | $5.65 | $2.09 |
| Resistance Level | $8.90 | $2.58 |
| Average True Range (ATR) | 0.65 | 0.16 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 40.77 | 16.28 |
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.